Adherence to the Antiemesis National Comprehensive Cancer Network (NCCN) Guideline

Adherence to the Antiemesis National Comprehensive Cancer Network (NCCN) Guideline in Chinese Patients of Gynecologic Malignancies

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03740672

Enrollment

1000

Registered

2018-11-14

Start date

2018-11-22

Completion date

2019-12-01

Last updated

2018-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy-induced Nausea and Vomiting, Gynecologic Cancer

Brief summary

This study aims to investigate the adherence to the antiemesis NCCN guideline in Chinese patients of gynecologic malignancies, who are given chemotherapy treatment. The risk of chemotherapy induced nausea and vomiting (CINV) is calculated by the questionnaire supported by the website CINV Risk Assessment (http://www.riskcinv.org/).

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Inclusion criteria

* Good performance status * Aged 18 years or older * Signed an approved informed consents

Exclusion criteria

* Not meeting all of the inclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
risk of chemotherapy induced nausea and vomiting	One year	The risk of chemotherapy induced nausea and vomiting is calculated by the questionnaire supported by the website CINV Risk Assessment (http://www.riskcinv.org/). The difference of patients adhered to and not to NCCN guideline is compared.

Countries

China

Contacts

Primary ContactLei Li, M.D.

lileigh@163.com8613911988831

Outcome results